April 29th 2024
New data from the DESTINY-Breast06 trial indicate that trastuzumab deruxtecan could become a new standard of care for patients with HER2-low and HER2-ultralow metastatic breast cancer.
Medical Crossfire®: How Have HER2-Low Expressing Breast Cancers and Novel Advances in the Field Redefined Care As We Knew It?
View More
Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?
View More
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Show Me Your Care Plan: Nursing Considerations for Managing Breast Cancer Patients
View More
Community Practice Connections™: The Newest Frontier in HR+ Breast Cancer—Targeting ESR1 Mutations with Next-Generation Endocrine Therapy
View More
Clinical Case Vignette Series™: 40th Annual Miami Breast Cancer Conference®
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
HER2+ Breast Cancer Tumor Board: Navigating Current and Evolving Strategies from Early Stages to Metastases
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Show Me the Data®: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® West
July 12-13, 2024
Register Now!
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Community Practice Connections®: Evaluating the Evolving Treatment Landscape for mHR+ Breast Cancer-How to Personalize Care and Improve Patient Outcomes
View More
Community Practice Connections™: Leveraging Multidisciplinary Teams in Early-Stage Breast Cancer When the Goal Is Cure
View More
Community Practice Connections™: 22nd Annual International Congress on the Future of Breast Cancer®
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
22nd Annual School of Breast Oncology
November 7-9, 2024
Register Now!
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Updated Guidelines Recommend Adding Pembrolizumab to Neoadjuvant Chemotherapy in TNBC
June 17th 2022The ASCO’s expert panel released updated recommendations of pembrolizumab in combination with neoadjuvant chemotherapy for patients with stage II or stage III early triple-negative breast cancer
Read More
Efficacy of Neoadjuvant/Adjuvant Pembrolizumab in TNBC
June 16th 2022Lajos Pusztai, MD, DPhil, discusses multiple analyses of the phase 3 KEYNOTE-522 clinical trial of pembrolizumab plus chemotherapy administered in the neoadjuvant or adjuvant setting to patients with triple-negative breast cancer versus placebo plus chemotherapy.
Watch
Consistent Survival Outcomes With Ribociclib Dose Reductions in HR+/HER2- Advanced Breast Cancer
June 9th 2022Patients with hormone receptor–positive, HER2-negative advanced breast cancer who had dose modifications of ribociclib had comparable overall survival outcomes to those given the standard dose.
Read More
LUMINA Study Revels Radiotherapy is Not Needed for Some Luminal A Breast Cancers
June 7th 2022According to Timothy J. Whelan, MD, FASCO, radiotherapy is an inconvenient treatment. It can last daily for up to 5 weeks and it is a costly therapy. Study results shows that is can safely be omitted in the treatment of some patients with luminal A breast cancers.
Read More
Risk Factors Linked to Discontinuation of Adjuvant Abemaciclib in HR+/HER– Breast Cancer
June 6th 2022Several key risk factors seen in the monarchE trial of adjuvant abemaciclib could help early monitoring of patients with hormone receptor–positive, HER2-negative, node-positive high-risk early breast cancer to prevent discontinuation.
Read More
Benefit of Alpelisib/Fulvestrant Combo in HR+/HER- Breast Cancer Confirmed With Biomarker Analysis
June 5th 2022Combination of alpelisib and fulvestrant shows clinical benefit in patients with hormone receptor–positive, HER2-negative advanced breast cancer regardless of gene mutation status, according to a retrospective biomarker analysis.
Read More
Treatment with ribociclib and an alternate endocrine therapy after progression on a prior CDK4/6 inhibitor improved progression-free survival over placebo and endocrine therapy in patients with HR-positive, HER2-negative unresectable or metastatic breast cancer, according to results of the randomized phase 2 MAINTAIN trial.
Read More
Patritumab Deruxtecan Elicits Promising Response in HER3-Expressing mBC
June 4th 2022According to Ian E. Krop, MD, PhD, patritumab deruxtecan is responsible for producing clinically meaningful and durable antitumor activity in patients with HER3-expressing metastatic breast cancer, warranting further research.
Read More
DESTINY-Breast03 Update Reinforces Safety of Trastuzumab Deruxtecan in Metastatic Breast Cancer
June 4th 2022A safety follow-up analysis of the randomized phase 3 DESTINY-Breast03 study reinforced the risk-benefit profile of trastuzumab deruxtecan compared with trastuzumab emtansine in patients with HER2-positive unresectable or metastatic breast cancer
Read More
Sacituzumab Govitecan Reduces Risk of Disease Progression in HR+/HER2- Metastatic Breast Cancer
June 4th 2022A 34% reduction in the risk of disease progression was observed with sacituzumab govitecan vs standard chemotherapy as treatment of patients with hormone-receptor-positive and HER2-negative metastatic breast cancer.
Read More
Roundtable Discussion: Graff and Participants Debate Treatment Choices in TNBC
June 1st 2022During a Targeted Oncology case-based roundtable event, Stephanie L. Graff, MD, discussed the case of a patient with triple-negative breast cancer who progressed following adjuvant chemotherapy and frontline carboplatin treatment.
Read More